Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results

BACKGROUND: Pirfenidone was approved by the European Medicines Agency and introduced in most European countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months with respect to targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Salih, Goran Nadir, Shaker, Saher Burhan, Madsen, Helle Dall, Bendstrup, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018656/
https://www.ncbi.nlm.nih.gov/pubmed/27616539
http://dx.doi.org/10.3402/ecrj.v3.32608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018656/
https://www.ncbi.nlm.nih.gov/pubmed/27616539
http://dx.doi.org/10.3402/ecrj.v3.32608

Ejemplares similares